期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

难治性妇科恶性肿瘤的处理策略 被引量：2

原文传递
导出
摘要 妇科恶性肿瘤已成为严重威胁妇女健康的主要疾病。妇科恶性肿瘤的治疗尽管几经改进，仍有相当一部分患者治疗无效或复发。一旦发生治疗无效或复发，再次治疗方案的选择非常棘手，因这些患者多数有手术、化疗或放疗史，常规治疗方法难以改善其疗效。因此，对这些难治性妇科恶性肿瘤的处理一直以来是临床治疗的难点，也是妇科肿瘤医师所面临的最大挑战。
作者 向阳 孙建衡
机构地区 中国医学科学院中国协和医科大学北京协和医院妇产科 中国医学科学院中国协和医科大学肿瘤医院妇瘤科
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2008年第10期721-723,共3页 Chinese Journal of Obstetrics and Gynecology
关键词 妇科恶性肿瘤 难治性 治疗方案 妇科肿瘤医师 妇女健康 治疗方法 临床治疗 复发
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献11

  • 1Kesic V. Management of cervical cancer. Eur J Surg 0ncol,2006, 32:832-837.
  • 2Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol,2007,18:409-420.
  • 3Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol 0ncol,2008, 108:53-57.
  • 4Ferrero JM, Weber B, Geay JF,et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse : a GINECO phase II trial. Ann Oncol,2007,18:263-268.
  • 5Mutch DG, Orlando M, Goss T, et al. Randomized phase Ⅲ trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol, 2007,25:2811-2818.
  • 6李小平,崔恒,周敬伟,魏丽惠,王建六,赵彦,王悦,王世军,祝洪澜,董丽,张虹.IAP方案治疗复发及耐药性卵巢上皮性癌的临床分析[J].中华妇产科杂志,2008,43(10):724-727. 被引量：4
  • 7Hatter P, du Bois A. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curt Opin Onco1,2005 ,17 :505-514.
  • 8Stehman FB, Look KY. Carcinoma of the vulva. Obstet Gynecol, 2006,107:719-733.
  • 9Xiang Y, Sun Z, Wan X, et al. EMA/EP chemotherapy for chemorefractory gestalional trophoblastic tumor. J Reprod Med, 2004,49:443-446.
  • 10冯凤芝,向阳,曹杨,李雷,万希润,杨秀玉.手术联合化疗治疗耐药性妊娠滋养细胞肿瘤的疗效分析[J].中华妇产科杂志,2008,43(10):728-731. 被引量：18

二级参考文献23

  • 1张颖,向阳,任彤,万希润,杨秀玉.恶性滋养细胞肿瘤肺转移患者肺叶切除术指征的探讨[J].中华妇产科杂志,2005,40(2):83-86. 被引量：13
  • 2孙崟,向阳,万希润,杨秀玉.绒毛膜癌复发的影响因素分析[J].中华妇产科杂志,2006,41(5):329-332. 被引量：7
  • 3Herrin VE, Thigpen JT. Chemotherapy for ovarian cancer: current concepts. Semin Surg Oncol, 1999,17 : 181-188.
  • 4Misset JL, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol,2000,35:75-93.
  • 5Muggia FM. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Semin Oncol, 2004,31 : 17-24.
  • 6Fu S, Kavanagh J J, Hu W, et al. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer,2006,16:1717- 1732.
  • 7Faul C, Gerszten K, Edwards R, et al. A phase Ⅰ/Ⅱ study of hypofractionated whole abdominal radiation therapy in patients with chemoresistant ovarian carcinoma: Kamofsky score determines treatment outcome. Int J Radiat Oncol Biol Phys,2000,47:749-754.
  • 8Therasse P, Arbuck SG, Eisenhauer EA,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst ,2000 ,92 :205-216.
  • 9Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125 : a North Thames Ovary Group Study. Ann Oncol, 1996,7:361-364.
  • 10Raymond E, Chaney SG, Taamma A,et al. Oxaliplatin: a review of preelinical and clinical studies. Ann 0nco1,1998,9:1053-1071.

共引文献20

同被引文献19

  • 1Lurain JR,Nejad B.Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.Gynecol Oncol,2005,97:618-623.
  • 2Matsui H,Suzuka K,Yamazawa K,et al.Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy.Gynecol Oncol,2005,96:616-620.
  • 3Parmar MK,Ledermann JA,Colombo N,et al.Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial Lancet,2003,361:2099-2106.
  • 4Pfisterer J,Plante M,Vergote I,et al.Gemcitabine plus carboplatin compared with carboplatin in patients with platinumsensitive recurrent ovarian cancer:an intergroup trial of the AGOOVAR,the NCIC CTG,and the EORTC GCG.J Clin Oncol,2006,24:4699-4707.
  • 5Monk BJ,Herzog T,Kaye S,et al.A randomized phase Ⅲ study of trabectedin with pegylated liposomal doxorubicin (PLD) vs PLD in relapsed,recurrent ovarian cancer OVA-301.Ann Oncol,2008,19:1-4.
  • 6Bristow RE,Puri I,Chi DS.Cytoreductive surgery for recurrent ovarian cancer:a meta-analysis.Gynecol Oncol,2009,112:265-274.
  • 7Harter P,du Bois A.The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence.Curr Opin Oncol,2005,17:505-514.
  • 8Lenhard SM,Burges A,Johnson TR,et al.Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.Eur J Obstet Gynecol Reprod Biol,2008,140:263-268.
  • 9Kesic V.Management of cervical cancer.Eur J Surg Oncol,2006,32:832-837.
  • 10Dinh P,Harnett P,Piccart-Gebhart MJ,et al.New therapies for ovarian cancer:cytotoxics and molecularly targeted agents.Crit Rev Oncol Hematol,2008,67:103-112.

引证文献2

二级引证文献3

中华妇产科杂志
2008年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部